Cala Health

Cala Health is a commercial-stage medical device company focused on non-invasive peripheral neuromodulation for movement disorders. Its core technology, the Cala kIQ System, uses patterned electrical stimulation (TAPS) at the wrist to disrupt pathological tremor signals, offering drug-free, on-demand relief. The company has achieved significant commercial milestones, including FDA clearance, Medicare coverage, and VA benefits coverage, supported by a growing body of clinical and real-world evidence. Cala operates a prescription-based business model, targeting the large and underserved essential tremor market.

Transcutaneous Afferent Patterned Stimulation (TAPS) - a non-invasive, wearable neuromodulation platform that delivers patterned electrical stimulation to peripheral nerves at the wrist to disrupt pathological tremor signals.

Cala competes with pharmacological treatments (e.g., propranolol, primidone) and invasive surgical procedures like Deep Brain Stimulation (DBS) and focused ultrasound. Its main differentiator is being a non-invasive, non-pharmacological, on-demand therapy. Potential future competitors include other non-invasive neuromodulation devices, though Cala currently has first-mover advantage with an FDA-cleared, Medicare-covered product for this specific indication.